stockrow
Saturday 7 November 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.
- Revenue
- +287.2%
- EPS
- +31.3%
- Free cash flow
- +105.9%
Quarter to September 2026, against a year earlier
4.09
0.42
−9.31%
Follow ALGS
Alert me
Aligos Therapeutics, Inc. (ALGS) P/E ratio
Aligos Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ACET Adicet Bio, Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| LITS Lite Strategy, Inc. compare | n/m |
| EDSA Edesa Biotech, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)